Standing up to Rising Prescription Drug Costs Increases Access to Breakthrough Medications

Why It Matters

Reducing Yeztugo’s cost expands access to a highly effective HIV‑prevention therapy, potentially lowering new infections and associated healthcare spending.

Key Takeaways

• CVS Caremark secured price relief for $28k‑yearly Yeztugo.
• Twice‑yearly injection improves PrEP adherence versus daily pills.
• Affordable access targets rising HIV rates in Black, Hispanic men.
• Negotiated pricing showcases PBM leverage to curb drug costs.
• Expanded options give patients choice across pills and injectables.

Pulse Analysis

The United States saw over 39,000 new HIV infections in 2023, a trend driven largely by disparities affecting Black and Hispanic men. Preventive measures such as pre‑exposure prophylaxis (PrEP) have proven essential, yet cost remains a formidable barrier. Traditional daily pills, while effective, suffer from adherence challenges, especially among populations facing socioeconomic hurdles. As insurers and employers grapple with rising healthcare expenditures, the need for affordable, high‑impact interventions has never been more urgent.

Enter Yeztugo (lenacapavir), a breakthrough long‑acting injectable that delivers near‑total protection with just two doses per year. Its extended dosing schedule simplifies treatment regimens, reducing the daily decision‑making burden that often leads to missed doses. However, the drug’s initial wholesale price—$28,000 annually—placed it out of reach for most patients who could benefit most. CVS Caremark’s recent negotiation with the manufacturer secured a discount that lowers out‑of‑pocket costs for its clients, illustrating how pharmacy benefit managers can wield scale to negotiate more sustainable pricing for life‑changing therapies.

The broader implication is a shifting paradigm in drug pricing negotiations. As PBMs like CVS Caremark demonstrate the ability to extract meaningful discounts on premium products, other stakeholders—employers, unions, and government programs—may follow suit, pressuring manufacturers to adopt value‑based pricing models. Greater affordability of high‑efficacy PrEP options could improve adherence rates, reduce HIV incidence, and ultimately lower long‑term medical costs. For the healthcare market, this signals a move toward aligning commercial incentives with public health outcomes, a trend likely to accelerate as more breakthrough therapies enter the market.